Amphastar Pharmaceuticals (AMPH) EBITDA (2013 - 2026)

Amphastar Pharmaceuticals has reported EBITDA for 14 years, with the latest figure at $39.7 million in Q2 2026.

• On a quarterly basis, EBITDA fell 5.82% year-over-year to $39.7 million in Q2 2026; TTM through Jun 2026 was $114.3 million, a 37.09% decrease from a year earlier, with the FY2025 full-year figure at $140.4 million, down 31.65% from the prior year.
• EBITDA was $39.7 million for Q2 2026 at Amphastar Pharmaceuticals, up from $13.6 million in the prior quarter.
• The five-year high for EBITDA was $72.7 million in Q3 2023, with the low at $13.6 million in Q1 2026.
• Average EBITDA over 5 years is $39.1 million, with a median of $37.6 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2026: EBITDA jumped 212.89% in 2023, then plunged 63.45% in 2026.
• Over 5 years, EBITDA stood at $37.8 million in 2022, then surged by 42.68% to $54.0 million in 2023, then decreased by 16.37% to $45.1 million in 2024, then decreased by 21.13% to $35.6 million in 2025, then climbed by 11.58% to $39.7 million in 2026.
• The last three EBITDA figures came in at $39.7 million (Q2 2026), $13.6 million (Q1 2026), and $35.6 million (Q4 2025), per Business Quant data.